New tax inversion rules put damper on pending Pfizer-Allergan deal

An expected deal between pharmaceutical giants Pfizer and Allergan that’s expected to be worth up to $ 380 a share could become less lucrative under new U.S. Treasury rules designed to diminish the benefits of cross-border transactions.
Modern Healthcare Breaking News

Pharmaceutical Stocks


© 2017 Drugs News All rights reserved.       Privacy Policy       Contact Us